Gilles Grateau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gilles Grateau has a total of 103 co-authors. Here are the top co-authors by number of shared publications:
- Sophie Georgin-Lavialle
Department of Internal Medicine, DMU 3ID, FHU INFLAMME, ERN RITA, Reference Centre for Autoinflammatory Diseases and Amyloidosis (CEREMAIA),Tenon Hospital, Sorbonne University, APHP, Paris, France
13 shared publications - Véronique Hentgen
Center Hospitalier de Versailles, Le Chesnay, France
7 shared publications - David Buob
Department of Anatomy and Cytopathology Tenon Hospital Assistance Publique–Hôpitaux de Paris (AP‐HP) Paris France
5 shared publications - Isabelle Koné-Paut
Department of Pediatric Rheumatology, National Reference Centre for Auto-Inflammatory Diseases and Amyloidosis of Inflammatory Origin (CEREMAIA), Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), University of Paris Saclay Le Kremlin Bicêtre, Paris, France
5 shared publications - Alexandre Belot
Centre International de Recherche en Infectiologie, Inserm, U1111, CNRS, UMR5308, École Normale Supérieure de Lyon, Lyon, France
3 shared publications - Irina Giurgea
Molecular Genetics Unit Trousseau Hospital Sorbonne University Paris France
3 shared publications
Latest Publications
- Open Access
- 7 September 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (5) , 709-718
AA amyloidosis in the four historical monogenic autoinflammatory diseases: Clinical burden and insights from a retrospective referral‐centre study
Background: AA amyloidosis (AAA) remains a life‐threatening yet largely preventable complication of monogenic autoinflammatory diseases (AIDs). Methods: We retrospectively described patients with AAA secondary to one of the four historical monogenic AIDs (familial Mediterranean fever [FMF], cryopyrin‐associated periodic syndrome [CAPS], mevalonate kinase deficiency [MKD] and tumour necrosis factor receptor–associated periodic syndrome [TRAPS]) followed at the French National Referral Centre for Monogenic AIDs and Inflammatory Amyloidosis (2012–2025). Results: Among 181 patients followed for AAA, 50 (28%) had one of the four monogenic AIDs (FMF n = 41, CAPS n = 4, MKD n = 3, TRAPS n = 2), corresponding to an overall prevalence of 5% among all patients with monogenic AIDs. AAA preceded the diagnosis of the underlying AID in 40% of patients, particularly those with non‐FMF diseases. Disease burden remained high, with 46% of patients requiring kidney transplantation, whereas mortality reached 26% during follow‐up. Conclusion: AAA continues to reflect delayed diagnosis, highlighting the need for increased awareness among adult healthcare providers, systematic genetic evaluation of unexplained AAA and early inflammatory control.
- 7 September 2026
- Published by Wiley in Journal of Internal Medicine
- Vol. 300 (5) , 709-718
Open AccessAA amyloidosis in the four historical monogenic autoinflammatory diseases: Clinical burden and insights from a retrospective referral‐centre study
Background: AA amyloidosis (AAA) remains a life‐threatening yet largely preventable complication of monogenic autoinflammatory diseases (AIDs). Methods: We retrospectively described patients with AAA secondary to one of the four historical monogenic AIDs (familial Mediterranean fever [FMF], cryopyrin‐associated periodic syndrome [CAPS], mevalonate kinase deficiency [MKD] and tumour necrosis factor receptor–associated periodic syndrome [TRAPS]) followed at the French National Referral Centre for Monogenic AIDs and Inflammatory Amyloidosis (2012–2025). Results: Among 181 patients followed for AAA, 50 (28%) had one of the four monogenic AIDs (FMF n = 41, CAPS n = 4, MKD n = 3, TRAPS n = 2), corresponding to an overall prevalence of 5% among all patients with monogenic AIDs. AAA preceded the diagnosis of the underlying AID in 40% of patients, particularly those with non‐FMF diseases. Disease burden remained high, with 46% of patients requiring kidney transplantation, whereas mortality reached 26% during follow‐up. Conclusion: AAA continues to reflect delayed diagnosis, highlighting the need for increased awareness among adult healthcare providers, systematic genetic evaluation of unexplained AAA and early inflammatory control.
- 26 August 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 30 (7) , 297-299
Transition to Adult Care in Autoinflammatory Diseases
Background: Transitioning from pediatric to adult care is a critical step for individuals with autoinflammatory diseases, requiring effective programs to ensure continuity of care and disease management. Despite various recommendations, the effectiveness of transition programs, particularly in monogenic autoinflammatory diseases, remains understudied. Methods: A single-center medical records review study was conducted at the French National Reference Center for Adult Autoinflammatory Diseases in Tenon Hospital from 2017 to 2023. All patients who had consulted for the first time between the ages of 15 and 30 years and had received care for an autoinflammatory disease during childhood were included. The patients were classified according to whether they had undergone a transition, defined as either no transition, simple transition (referral letter), or joint transition (pediatrician and adult physician consultation). Results: One hundred eleven patients (median age, 18 years) were included. Patients who consulted without transition started adult follow-up and were followed up less regularly than those who underwent the transition process (p < 0.001 and p = 0.028). In patients with familial Mediterranean fever, the absence of a formal transition was associated with poorer disease control at baseline (p = 0.019). The type of transition did not impact disease control during follow-up. Conclusions: Participation in a transition program is associated with earlier and more regular follow-up in adulthood. Although transition type did not significantly impact disease control during follow-up in familial Mediterranean fever, the potential benefit of joint consultation extends beyond consultation frequency and disease outcomes, encompassing patient perspectives and self-management abilities. This study highlights the significance of collaborative transition programs in AIDs.
- 26 August 2024
- Published by Wolters Kluwer Health in JCR: Journal of Clinical Rheumatology
- Vol. 30 (7) , 297-299
Transition to Adult Care in Autoinflammatory Diseases
Background: Transitioning from pediatric to adult care is a critical step for individuals with autoinflammatory diseases, requiring effective programs to ensure continuity of care and disease management. Despite various recommendations, the effectiveness of transition programs, particularly in monogenic autoinflammatory diseases, remains understudied. Methods: A single-center medical records review study was conducted at the French National Reference Center for Adult Autoinflammatory Diseases in Tenon Hospital from 2017 to 2023. All patients who had consulted for the first time between the ages of 15 and 30 years and had received care for an autoinflammatory disease during childhood were included. The patients were classified according to whether they had undergone a transition, defined as either no transition, simple transition (referral letter), or joint transition (pediatrician and adult physician consultation). Results: One hundred eleven patients (median age, 18 years) were included. Patients who consulted without transition started adult follow-up and were followed up less regularly than those who underwent the transition process (p < 0.001 and p = 0.028). In patients with familial Mediterranean fever, the absence of a formal transition was associated with poorer disease control at baseline (p = 0.019). The type of transition did not impact disease control during follow-up. Conclusions: Participation in a transition program is associated with earlier and more regular follow-up in adulthood. Although transition type did not significantly impact disease control during follow-up in familial Mediterranean fever, the potential benefit of joint consultation extends beyond consultation frequency and disease outcomes, encompassing patient perspectives and self-management abilities. This study highlights the significance of collaborative transition programs in AIDs.
- 30 November 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (4) , E538-E542
Systemic inflammatory trunk recurrent acute macular eruption (SITRAME): A new auto‐inflammatory syndrome in adult?
- 30 November 2022
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 37 (4) , E538-E542
Systemic inflammatory trunk recurrent acute macular eruption (SITRAME): A new auto‐inflammatory syndrome in adult?
- 30 April 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 136 (2) , 85-93
Neurological manifestations in mevalonate kinase deficiency: A systematic review
- 30 April 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 136 (2) , 85-93
Neurological manifestations in mevalonate kinase deficiency: A systematic review
- 18 December 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (5) , E363-E365
Tattooing and autoinflammatory diseases: a study among 197 French patients from the JIR cohort
- 18 December 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 36 (5) , E363-E365
Tattooing and autoinflammatory diseases: a study among 197 French patients from the JIR cohort
- 27 June 2021
- Published by Taylor & Francis in Amyloid
- Vol. 28 (4) , 273-274
Abnormal electrochemical skin conductance values in patients with AA amyloidosis
Clinical manifestations are scarce in AA amyloidosis and, contrary to other types of amyloidosis, involvement of the peripheral nervous system, including the autonomic nervous system, was rarely re...
- 27 June 2021
- Published by Taylor & Francis in Amyloid
- Vol. 28 (4) , 273-274
Abnormal electrochemical skin conductance values in patients with AA amyloidosis
Clinical manifestations are scarce in AA amyloidosis and, contrary to other types of amyloidosis, involvement of the peripheral nervous system, including the autonomic nervous system, was rarely re...
- 23 June 2021
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 51 (1) , 42-49
Is neutrophilic dermatosis a manifestation of familial Mediterranean fever?
Objectives: Familial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disease. It is associated with MEFV mutations. Its main features are recurrent episodes of fever and serositis. Patients can display dermatological manifestations such as erysipelas-like erythema, generally considered as a neutrophilic dermatosis (ND). It has been suggested that FMF can be associated with other types of ND. Our aim was to perform a systematic review of the literature to assess the link between ND and FMF. Method: A systematic review of the literature was performed using MEDLINE from 1946 to 2018. Three independent investigators identified reports of non-erysipelas-like erythema neutrophilic dermatosis (NEND) associated with FMF, selected the criteria to establish the diagnosis of FMF and ND, and evaluated the link between the two conditions. FMF-associated NEND was supported by confirmation of both diagnoses and exclusion of other causes of ND. Results: Eighteen articles were selected. Nine articles reported FMF patients with the following NEND: neutrophilic panniculitis (n = 4), Sweet syndrome (n = 6), and pyoderma gangrenosum (n = 1). None of these cases was supported by histological confirmation, fulfilled diagnostic criteria for definitive or probable FMF, or confirmed the exclusion of all the most frequent diseases associated with NEND. As a result, there is insufficient evidence to support a potential relationship between NEND and FMF. Conclusions: The association between FMF and NEND remains unclear. In FMF patients with NEND, every differential diagnosis and alternative cause of NEND should be excluded before drawing any conclusions about a potential causal relationship.
- 23 June 2021
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 51 (1) , 42-49
Is neutrophilic dermatosis a manifestation of familial Mediterranean fever?
Objectives: Familial Mediterranean fever (FMF) is the most frequent monogenic autoinflammatory disease. It is associated with MEFV mutations. Its main features are recurrent episodes of fever and serositis. Patients can display dermatological manifestations such as erysipelas-like erythema, generally considered as a neutrophilic dermatosis (ND). It has been suggested that FMF can be associated with other types of ND. Our aim was to perform a systematic review of the literature to assess the link between ND and FMF. Method: A systematic review of the literature was performed using MEDLINE from 1946 to 2018. Three independent investigators identified reports of non-erysipelas-like erythema neutrophilic dermatosis (NEND) associated with FMF, selected the criteria to establish the diagnosis of FMF and ND, and evaluated the link between the two conditions. FMF-associated NEND was supported by confirmation of both diagnoses and exclusion of other causes of ND. Results: Eighteen articles were selected. Nine articles reported FMF patients with the following NEND: neutrophilic panniculitis (n = 4), Sweet syndrome (n = 6), and pyoderma gangrenosum (n = 1). None of these cases was supported by histological confirmation, fulfilled diagnostic criteria for definitive or probable FMF, or confirmed the exclusion of all the most frequent diseases associated with NEND. As a result, there is insufficient evidence to support a potential relationship between NEND and FMF. Conclusions: The association between FMF and NEND remains unclear. In FMF patients with NEND, every differential diagnosis and alternative cause of NEND should be excluded before drawing any conclusions about a potential causal relationship.
- 23 December 2020
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 75 (6) , e13966
Infections and AA amyloidosis: An overview
Background: Amyloidoses are a heterogeneous group of systemic diseases characterised by extracellular accumulation of insoluble amyloid fibrils derived from unfolded proteins. Inflammatory (AA) amyloidosis can complicate various inflammatory disorders that are associated with a sustained acute phase response and serum amyloid A (SAA) protein overproduction. Chronic infections were the first recognised cause of amyloidoses. However, with the better management of underlying diseases, the frequency of AA amyloidosis is decreasing.Purpose: The aim of this overview was to discuss the several infections associated with AA amyloidosis and the relative frequency of infections as aetiological factors.Methods: A search of the literature was performed using the PubMed database using the MeSH terms “Amyloidosis” and “Infections,” from inception to December 31st, 2019. Articles written in other languages than English or French were excluded.Results: The frequency of AA amyloidosis secondary to infections decreased from more than 50% to less than 20% after the 2000s, with a parallel increase in the frequency of AA amyloidosis secondary to inflammatory diseases and to an unknown cause.Conclusion: Whereas new antibiotics have been developed and sanitary conditions are better, infections still represent 5%‐30% of the causes of AA amyloidosis, including in developed countries. These data argue for better screening of chronic infections to prevent AA amyloidosis and the development of new strategies to manage recurrent infections.
- 23 December 2020
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 75 (6) , e13966
Infections and AA amyloidosis: An overview
Background: Amyloidoses are a heterogeneous group of systemic diseases characterised by extracellular accumulation of insoluble amyloid fibrils derived from unfolded proteins. Inflammatory (AA) amyloidosis can complicate various inflammatory disorders that are associated with a sustained acute phase response and serum amyloid A (SAA) protein overproduction. Chronic infections were the first recognised cause of amyloidoses. However, with the better management of underlying diseases, the frequency of AA amyloidosis is decreasing.Purpose: The aim of this overview was to discuss the several infections associated with AA amyloidosis and the relative frequency of infections as aetiological factors.Methods: A search of the literature was performed using the PubMed database using the MeSH terms “Amyloidosis” and “Infections,” from inception to December 31st, 2019. Articles written in other languages than English or French were excluded.Results: The frequency of AA amyloidosis secondary to infections decreased from more than 50% to less than 20% after the 2000s, with a parallel increase in the frequency of AA amyloidosis secondary to inflammatory diseases and to an unknown cause.Conclusion: Whereas new antibiotics have been developed and sanitary conditions are better, infections still represent 5%‐30% of the causes of AA amyloidosis, including in developed countries. These data argue for better screening of chronic infections to prevent AA amyloidosis and the development of new strategies to manage recurrent infections.
- 1 April 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (4) , 791-798.e2
Somatic Mosaic NLRP3 Mutations and Inflammasome Activation in Late-Onset Chronic Urticaria
- 1 April 2020
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 140 (4) , 791-798.e2
Somatic Mosaic NLRP3 Mutations and Inflammasome Activation in Late-Onset Chronic Urticaria
- 31 July 2019
- Published by Taylor & Francis in Amyloid
- Vol. 26 (4) , 197-202
Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review
Introduction: HHV8-negative Castleman disease (CD) is classified as hyaline vascular (HV) type, or mixed or plasma cell (PC) types. It may present as multicentric CD (MCD) or unicentric CD (UCD). CD is a rare cause of AA amyloidosis (AAA). We aimed to report the main features of CD with secondary AAA through a description of new cases and a systematic literature review. Patients and methods: New cases were identified from the French National Reference Center for AAA. A systematic literature review was performed to identify HHV8-negative CD cases associated with AAA. Results: Thirty-seven patients were analysed, consisting of two new cases and 35 from literature. Twenty-three had UCD and 14 had MCD. PC was the main histologic subtype (n = 25; 68%) in both UCD and MCD patients. Surgical excision of UCD was performed in 21 patients (91%) with a favourable outcome, except for four patients (19%). Clinical and biologic remission was achieved in six patients with MCD (43%), all of whom were treated with anti-interleukin-6 (IL-6) therapy. Conclusions: AAA is a rare complication of CD, namely idiopathic MCD and UCD presenting with the PC histologic subtype. Surgical excision of UCD should be the first-line treatment whenever possible, while anti-IL-6 therapies seem effective for MCD.
- 31 July 2019
- Published by Taylor & Francis in Amyloid
- Vol. 26 (4) , 197-202
Epidemiology of Castleman disease associated with AA amyloidosis: description of 2 new cases and literature review
Introduction: HHV8-negative Castleman disease (CD) is classified as hyaline vascular (HV) type, or mixed or plasma cell (PC) types. It may present as multicentric CD (MCD) or unicentric CD (UCD). CD is a rare cause of AA amyloidosis (AAA). We aimed to report the main features of CD with secondary AAA through a description of new cases and a systematic literature review. Patients and methods: New cases were identified from the French National Reference Center for AAA. A systematic literature review was performed to identify HHV8-negative CD cases associated with AAA. Results: Thirty-seven patients were analysed, consisting of two new cases and 35 from literature. Twenty-three had UCD and 14 had MCD. PC was the main histologic subtype (n = 25; 68%) in both UCD and MCD patients. Surgical excision of UCD was performed in 21 patients (91%) with a favourable outcome, except for four patients (19%). Clinical and biologic remission was achieved in six patients with MCD (43%), all of whom were treated with anti-interleukin-6 (IL-6) therapy. Conclusions: AAA is a rare complication of CD, namely idiopathic MCD and UCD presenting with the PC histologic subtype. Surgical excision of UCD should be the first-line treatment whenever possible, while anti-IL-6 therapies seem effective for MCD.